JP2005507872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005507872A5 JP2005507872A5 JP2003521203A JP2003521203A JP2005507872A5 JP 2005507872 A5 JP2005507872 A5 JP 2005507872A5 JP 2003521203 A JP2003521203 A JP 2003521203A JP 2003521203 A JP2003521203 A JP 2003521203A JP 2005507872 A5 JP2005507872 A5 JP 2005507872A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- och
- phenyl
- conr
- attached
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- -1 C 1 -C 6 alkyl Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical group C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 claims 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical group C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31213501P | 2001-08-14 | 2001-08-14 | |
| PCT/US2002/021316 WO2003016276A2 (en) | 2001-08-14 | 2002-08-06 | 3-substituted oxindole beta-3 agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005507872A JP2005507872A (ja) | 2005-03-24 |
| JP2005507872A5 true JP2005507872A5 (https=) | 2006-01-05 |
Family
ID=23210032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003521203A Pending JP2005507872A (ja) | 2001-08-14 | 2002-08-06 | ３−置換オキシインドールβ３アゴニスト |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6911463B2 (https=) |
| EP (1) | EP1444224B1 (https=) |
| JP (1) | JP2005507872A (https=) |
| AT (1) | ATE325119T1 (https=) |
| AU (1) | AU2002318206A1 (https=) |
| DE (1) | DE60211199T2 (https=) |
| ES (1) | ES2262817T3 (https=) |
| WO (1) | WO2003016276A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1421078B1 (en) * | 2001-08-14 | 2006-09-27 | Eli Lilly And Company | Indole derivatives as beta-3 adrenergic agonists for the treatment of type 2 diabetes |
| AU2002347982A1 (en) * | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE Beta3 AGONISTS |
| AU2002353844A1 (en) * | 2001-11-20 | 2003-06-10 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| JP2005520805A (ja) | 2002-01-11 | 2005-07-14 | イーライ・リリー・アンド・カンパニー | ２−オキソ−ベンズイミダゾリル置換型エタノールアミン誘導体およびβ３アゴニストとしてのその使用 |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7435837B2 (en) | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| AR055054A1 (es) * | 2005-04-22 | 2007-08-01 | Wyeth Corp | Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina |
| AU2007307635A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| JP2010506853A (ja) * | 2006-10-12 | 2010-03-04 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物 |
| AR063280A1 (es) * | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| EP2527360B1 (en) | 2007-06-04 | 2015-10-28 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| CA2741024A1 (en) * | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| MX2012004373A (es) * | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| CA2788440A1 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| SI3004138T1 (sl) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Limited | Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB159945A (en) | 1919-11-28 | 1921-02-28 | Ernest Henry Jones | Removable covers for welding and like furnaces |
| CH624395A5 (https=) | 1976-01-08 | 1981-07-31 | Ciba Geigy Ag | |
| CA1116598A (en) | 1977-07-13 | 1982-01-19 | William T. Comer | 3-indolyl-tertiary butylaminopropanols |
| JPS6010021B2 (ja) * | 1979-01-31 | 1985-03-14 | 田辺製薬株式会社 | 新規ベンジルアルコ−ル誘導体及びその製法 |
| DE3423429A1 (de) | 1984-06-26 | 1986-01-02 | Beiersdorf Ag, 2000 Hamburg | Substituierte phenoxyalkylaminopropanole, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen |
| DE3426419A1 (de) * | 1984-07-18 | 1986-01-23 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US4728651A (en) | 1985-10-24 | 1988-03-01 | Hoechst-Roussel Pharmaceuticals Inc. | Antihypertensive thieno-isoxazoles and -pyrazoles |
| GB8528633D0 (en) | 1985-11-21 | 1985-12-24 | Beecham Group Plc | Compounds |
| US5451677A (en) | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113084A (en) | 1994-03-23 | 1999-01-26 | Sankyo Co | Thiazolidine and oxazolidine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| US5705515A (en) | 1994-04-26 | 1998-01-06 | Merck & Co., Inc. | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| US6075040A (en) * | 1996-09-05 | 2000-06-13 | Eli Lilly And Company | Selective β3 adrenergic agonists |
| ZA967892B (en) * | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| CA2257206A1 (en) | 1996-06-07 | 1997-12-11 | Gui-Bai Liang | Oxadiazole benzenesulfonamides as selective .beta.3 agonists for the treatment of diabetes and obesity |
| EP0827746B1 (en) | 1996-09-05 | 2002-04-03 | Eli Lilly And Company | Carbazole analogues as selective beta3 adrenergic agonists |
| US6011048A (en) * | 1997-01-28 | 2000-01-04 | Merck & Co., Inc. | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity |
| KR20000070568A (ko) | 1997-01-28 | 2000-11-25 | 폴락 돈나 엘. | 당뇨병 및 비만 치료를 위한 β3 효능제로서의 티아졸 벤젠설폰아미드 |
| AUPP796798A0 (en) | 1998-12-30 | 1999-01-28 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| JP2003055344A (ja) * | 1999-01-29 | 2003-02-26 | Dainippon Pharmaceut Co Ltd | ３，７−ジ置換インドール誘導体及びそれを含有する医薬組成物 |
| WO2001007026A2 (en) | 1999-07-22 | 2001-02-01 | Eli Lilly And Company | Improved method of treating type ii diabetes and obesity |
| WO2001035947A2 (en) | 1999-11-15 | 2001-05-25 | Eli Lilly And Company | Treating wasting syndromes with aryloxy propanolamines |
| AU1580001A (en) | 1999-11-15 | 2001-05-30 | Eli Lilly And Company | Process for the preparation of aryloxy propanolamines |
| US6420365B1 (en) | 2000-01-18 | 2002-07-16 | Neurogen Corporation | Imidazopyridines and related derivatives as selective modulators of bradykinin B2 receptors |
| ES2398097T3 (es) | 2000-07-13 | 2013-03-13 | Eli Lilly And Company | Agonistas adrenérgicos beta3 |
| EP1341759B1 (en) * | 2000-11-10 | 2006-06-14 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
-
2002
- 2002-08-06 AU AU2002318206A patent/AU2002318206A1/en not_active Abandoned
- 2002-08-06 WO PCT/US2002/021316 patent/WO2003016276A2/en not_active Ceased
- 2002-08-06 US US10/486,508 patent/US6911463B2/en not_active Expired - Fee Related
- 2002-08-06 JP JP2003521203A patent/JP2005507872A/ja active Pending
- 2002-08-06 ES ES02748081T patent/ES2262817T3/es not_active Expired - Lifetime
- 2002-08-06 DE DE60211199T patent/DE60211199T2/de not_active Expired - Fee Related
- 2002-08-06 AT AT02748081T patent/ATE325119T1/de not_active IP Right Cessation
- 2002-08-06 EP EP02748081A patent/EP1444224B1/en not_active Expired - Lifetime
-
2005
- 2005-03-16 US US11/082,106 patent/US7087635B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005507872A5 (https=) | ||
| JP2005514366A5 (https=) | ||
| JP2005518357A5 (https=) | ||
| JP2005539088A5 (https=) | ||
| JP2007510662A5 (https=) | ||
| WO2006098918A3 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2006526031A5 (https=) | ||
| JP2005501120A5 (https=) | ||
| JP2005510476A5 (https=) | ||
| JP2007508359A5 (https=) | ||
| JP2007518682A5 (https=) | ||
| JP2007522220A5 (https=) | ||
| JP2002543183A5 (https=) | ||
| JP2005502635A5 (https=) | ||
| JP2008044952A5 (https=) | ||
| JP2007519618A5 (https=) | ||
| JP2005517643A5 (https=) | ||
| JP2007534702A5 (https=) | ||
| JP2007502817A5 (https=) | ||
| JP2010520214A5 (https=) | ||
| JP2007508362A5 (https=) | ||
| NO20075734L (no) | Tiofenforbindelser og trombopoietin reseptoractivatorer | |
| NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
| JP2008546770A5 (https=) | ||
| JP2007531739A5 (https=) |